HILDEN, Germany & WALTHAM, Mass. & GERMANTOWN, Md.–(BUSINESS WIRE)–QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) and OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates, today announced signing a master companion diagnostics (CDx) agreement to develop a NGS CDx for OncXerna’s product candidate, Navicixizumab, and a non-exclusive license to the Xerna™ TME panel.
{iframe}https://www.businesswire.com/news/home/20210809005763/en/QIAGEN-and-OncXerna-Therapeutics-Sign-Licensing-and-Master-Companion-Diagnostic-Agreements{/iframe}